Catalytic Nanomedicine: Recurrent Pediatric Ependymoma Treated with Bionanocatalysts
Authors:   Department of Health Care, Autonomous Metropolitan University-Xochimilco, Mexico, López-Goerne Tessy , Padilla-Godínez Francisco J ,   Department of Health Care, Autonomous Metropolitan University-Xochimilco, Mexico, Gómez-López Esteban ,   Institute of Physics, Humboldt University of Berlin, Germany, álvarez-Amador Daniel ,   Department of Neurology and Neurosurgery, Children’s Hospital of Mexico “Federico Gomez”, Mexico, García-Beristain Juan Carlos ,   Department of Health Care, Autonomous Metropolitan University-Xochimilco, Mexico, González-Bondani Antonela ,   Department of Health Care, Autonomous Metropolitan University-Xochimilco, Mexico, Valiente Rafael ,   Department of Health Care, Autonomous Metropolitan University-Xochimilco, Mexico, González-Carranza Vicente ,   Department of Neurology and Neurosurgery, Children’s Hospital of Mexico “Federico Gomez”, Mexico, Carlos Manriquez Juan ,   Department of Cyclotron and Radiopharmacy, Doctors Hospital, Mexico, Navarro-Fernández José Omar ,   Department of Head and Neck, National Institute of Cancerology, Mexico, Santamaría Abel ,   Department of Health Care, Autonomous Metropolitan University-Xochimilco, Mexico
Published: January 2025

Background: Ependymomas, constituting about 10% of pediatric brain tumors are classified into three grades based on histology and molecular criteria. While typically arising from ependymal cells along cerebrospinal fluid pathways, exceptions exist regarding location for certain subtypes. Diagnosis relies on characteristic imaging findings and histopathological features, with intraventricular tumors often showing distinctive architectural patterns. Prognosis is significantly influenced by gross total resection and tumor location, with specific genomic alterations indicating varied outcomes. Current treatment involves surgical resection and radiotherapy, with chemotherapy’s efficacy remaining uncertain, and treatment guidelines have yet to incorporate molecular subtyping for personalized therapy. However, consensus favors microneurosurgical resection and local radiotherapy for specific molecular subtypes, notably PF-EPN-A type ependymomas in children over twelve months old.

Objective: The aim of this study was to assess the targeted eradication of tumor tissue using bionanocatalysts engineered specifically for DNA bond cleavage.

Methods: Bionanocatalysts were synthesized using established methods. These catalysts were then implanted into the tumor bed, and the progression was monitored using MRI scans.

Results: The patient showed a notable improvement in symptoms, accompanied by a considerable reduction in tumor size. Remarkably, no adverse side effects were detected. Even more impressively, after seven years, the patient, who was sent for palliative treatment, is still alive.

Conclusions: Bionanocatalysts demonstrated remarkable efficacy in eradicating a recurring pediatric ependymoma, even in a case initially slated for palliative care. Notably, no adverse effects were noted, underscoring the exceptional biocompatibility and targeted selectivity of these nanostructures exclusively towards tumorous tissue.